Abstract
Urate-lowering therapy (ULT) remains a big problem despite a recent progress in the study of gout. Low efficiency of ULT in the majority of cases is associated with its irrational use in both the past and the present. A certain skepticism of patients with gout is related in large part to the lack of improvement of signs and symptoms of disease. ULT control by qualified rheumatologists could play a significant role in enhancing its effectiveness.
References
1. Барскова В.Г. Хроническая подагра: причины развития, клинические проявления, лечение / В.Г. Барскова // Тер. архив. — 2010. — № 1. — С. 64-68.
2. Михневич Э. Ошибки и проблемы назначения аллопуринола пациентам с подагрой / Э. Михневич // Здравоохранение. — 2014. — № 3. — С. 27-31.
3. 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia / D. Khanna, J. Fitzgerald, P. Khanna [et al.] // Arthritis Care and Res. — 2012. — Vol. 10. — P. 1431-1446.
4. 2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis / D. Khanna, P. Khanna, J. Fitzgerald [et al.] // Arthritis Care and Res. — 2012. — Vol. 10. — P. 1447-1461.
5. Bardin T. Definition of hyperuricaemia and gouty conditions / T. Bardin, P. Richette // Curr. Opin. Rheumatol. — 2014. — Vol. 26. — P. 186-191.
6. Cellular characterization of the gouty thophus; quantitative analysis / N. Dalbeth, B. Pool, G. Gamble [et al.] // Arthritis Rheum. — 2010. — Vol. 62. — P. 1549-1556.
7. Chao J. A critical reappraisal of allopurinol dosing, safety and efficacy for hyperuricemia in gout / J. Chao, R. Terkeltaub // Curr. Rheum. Rep. — 2009. — Vol. 11. — P. 135-140.
8. Dalbeth N. Hyperuricaemia and gout: time for a new staging system / N. Dalbeth, L. Stamp // Ann. Rheum. Dis. — 2014. — Vol. 73. — P. 1598-1600.
9. Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy / M. Becker, P. MacDonald, B. Hunt [et al.] // Nucleosides Nucleotides Nucleic Acids. — 2008. — Vol. 27. — P. 585-591.
10. Diagnosis of gout in patients with asymptomatic hyperuricaemia: a pilot ultrasound study / D. De Miguel, G. Puig, C. Castillo [et al.] // Ann. Rheum. Dis. — 2012. — Vol. 71. — P. 157-158.
11. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricaemia in patients with gout / N. Dalbeth, S. Kumar, L. Stamp, P. Gow // J. Rheumatol. — 2006. — Vol. 33. — P. 1646-1650.
12. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout / F. Perez-Ruiz, A. Alonso-Ruiz, M. Calabozo [et al.] // Ann. Rheum. Dis. — 1998. — Vol. 57. — P. 545-549.
13. Epidemiology and management of gout in Taiwan: a nationwide population study / C.F. Kuo, M. Grainge, L.C. See [et al.] // Arthr. Res. Ther. — 2015. — Vol. 17. — ID 13.
14. EULAR evidence-based recommendations for gout. Part 2. Management. Report of a Task Force of the EULAR Standing Committee for International clinical studies including therapeutics / W. Zhang, M. Doherty, E. Pascual [et al.] // Ann. Rheum. Dis. — 2006. — Vol. 65. — P. 1312-1324.
15. Features of gout deposition in patients with gouty arthritis of the foot using dual-energy computed tomography / Y. Sun, L. Ma, Y. Zhou [et al.] // Int. J. Rheum. Dis. — 2015. — Vol. 18. — P. 560-567.
2. Михневич Э. Ошибки и проблемы назначения аллопуринола пациентам с подагрой / Э. Михневич // Здравоохранение. — 2014. — № 3. — С. 27-31.
3. 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia / D. Khanna, J. Fitzgerald, P. Khanna [et al.] // Arthritis Care and Res. — 2012. — Vol. 10. — P. 1431-1446.
4. 2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis / D. Khanna, P. Khanna, J. Fitzgerald [et al.] // Arthritis Care and Res. — 2012. — Vol. 10. — P. 1447-1461.
5. Bardin T. Definition of hyperuricaemia and gouty conditions / T. Bardin, P. Richette // Curr. Opin. Rheumatol. — 2014. — Vol. 26. — P. 186-191.
6. Cellular characterization of the gouty thophus; quantitative analysis / N. Dalbeth, B. Pool, G. Gamble [et al.] // Arthritis Rheum. — 2010. — Vol. 62. — P. 1549-1556.
7. Chao J. A critical reappraisal of allopurinol dosing, safety and efficacy for hyperuricemia in gout / J. Chao, R. Terkeltaub // Curr. Rheum. Rep. — 2009. — Vol. 11. — P. 135-140.
8. Dalbeth N. Hyperuricaemia and gout: time for a new staging system / N. Dalbeth, L. Stamp // Ann. Rheum. Dis. — 2014. — Vol. 73. — P. 1598-1600.
9. Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy / M. Becker, P. MacDonald, B. Hunt [et al.] // Nucleosides Nucleotides Nucleic Acids. — 2008. — Vol. 27. — P. 585-591.
10. Diagnosis of gout in patients with asymptomatic hyperuricaemia: a pilot ultrasound study / D. De Miguel, G. Puig, C. Castillo [et al.] // Ann. Rheum. Dis. — 2012. — Vol. 71. — P. 157-158.
11. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricaemia in patients with gout / N. Dalbeth, S. Kumar, L. Stamp, P. Gow // J. Rheumatol. — 2006. — Vol. 33. — P. 1646-1650.
12. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout / F. Perez-Ruiz, A. Alonso-Ruiz, M. Calabozo [et al.] // Ann. Rheum. Dis. — 1998. — Vol. 57. — P. 545-549.
13. Epidemiology and management of gout in Taiwan: a nationwide population study / C.F. Kuo, M. Grainge, L.C. See [et al.] // Arthr. Res. Ther. — 2015. — Vol. 17. — ID 13.
14. EULAR evidence-based recommendations for gout. Part 2. Management. Report of a Task Force of the EULAR Standing Committee for International clinical studies including therapeutics / W. Zhang, M. Doherty, E. Pascual [et al.] // Ann. Rheum. Dis. — 2006. — Vol. 65. — P. 1312-1324.
15. Features of gout deposition in patients with gouty arthritis of the foot using dual-energy computed tomography / Y. Sun, L. Ma, Y. Zhou [et al.] // Int. J. Rheum. Dis. — 2015. — Vol. 18. — P. 560-567.
Downloads
Download data is not yet available.